Congratulations to Scott Webster and Damian Mole and the rest of the team at Kynos Therapeutics on the news of their acquisition by Dr. Falk Pharma. 🎉 OCC have been delighted to support the Company from spinout to acquisition, and we look forward to seeing the use of this innovative therapeutic approach in the near future. 💡 🏥 To help us scale our activity, we follow an evergreen model, reinvesting our returns to help the next generation of companies. 💸 #spinout #innovation #pharma
Clinical stage biopharmaceutical company Dr. Falk Pharma has acquired University of Edinburgh spinout Kynos Therapeutics, to further develop its novel KMO inflammation inhibitors, initially for acute pancreatitis. Dr Susan Bodie, Head of Business Development for the College of Medicine and Veterinary Medicine at Edinburgh Innovations, said: “The journey from lab to clinic is long and arduous and, to see these inflammation inhibitors now much further along that path and on a trajectory to improve lives, is what we at Edinburgh Innovations are all about. “We are delighted for the founders, and for the University, which will see a return of funds managed by Old College Capital, our in-house venture investment team, continuing to support the most exciting ideas and technologies emerging from the University.” Read more➡https://lnkd.in/eiAuKckE The University of Edinburgh | College of Medicine & Veterinary Medicine, The University of Edinburgh | Andrea Taylor | Andrea Young| Damian Mole| Scott Webster| Institute for Regeneration and Repair| Scottish Enterprise| Epidarex Capital| IP Group plc| Jonathan Savidge #innovation #collaboration #pharma #spinout #acutepancreatitis #pancreatitis #researchanddevelopment
